Similar articles for PMID: 29669874

Year	Number of Results
2004	1
2008	1
2010	2
2011	1
2012	1
2013	2
2014	7
2015	7
2016	37
2017	18
2018	10
2019	14
2020	9
2021	2
2022	2
2024	0

1

Advances in Stroke 2017.

Bernhardt J, Zorowitz RD, Becker KJ, Keller E, Saposnik G, Strbian D, Dichgans M, Woo D, Reeves M, Thrift A, Kidwell CS, Olivot JM, Goyal M, Pierot L, Bennett DA, Howard G, Ford GA, Goldstein LB, Planas AM, Yenari MA, Greenberg SM, Pantoni L, Amin-Hanjani S, Tymianski M. Bernhardt J, et al. Stroke. 2018 May;49(5):e174-e199. doi: 10.1161/STROKEAHA.118.021380. Epub 2018 Apr 18. Stroke. 2018. PMID: 29669874 Review. No abstract available.

2

Reversal of direct oral anticoagulants.

Zhang XY, Desborough MJ, Shapiro S. Zhang XY, et al. Br J Hosp Med (Lond). 2017 Mar 2;78(3):165-169. doi: 10.12968/hmed.2017.78.3.165. Br J Hosp Med (Lond). 2017. PMID: 28277769 Review.

3

When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.

Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI; Subcommittee on Control of Anticoagulation. Levy JH, et al. J Thromb Haemost. 2016 Mar;14(3):623-7. doi: 10.1111/jth.13227. Epub 2016 Feb 17. J Thromb Haemost. 2016. PMID: 26911798 Free article. Review. No abstract available.

4

[Antidotes for the new oral anticoagulants: Reality and expectations].

Gómez-Outes A, Lecumberri R. Gómez-Outes A, et al. Med Clin (Barc). 2016 Jun 3;146(11):488-90. doi: 10.1016/j.medcli.2015.11.014. Epub 2016 Jan 6. Med Clin (Barc). 2016. PMID: 26776485 Spanish. No abstract available.

5

Introduction to direct oral anticoagulants and rationale for specific reversal agents.

Pollack CV Jr. Pollack CV Jr. Am J Emerg Med. 2016 Nov;34(11S):1-2. doi: 10.1016/j.ajem.2016.09.045. Epub 2016 Sep 28. Am J Emerg Med. 2016. PMID: 27697437 Free article. Review. No abstract available.

6

Reversal agents for non-vitamin K antagonist oral anticoagulants.

Levy JH, Douketis J, Weitz JI. Levy JH, et al. Nat Rev Cardiol. 2018 May;15(5):273-281. doi: 10.1038/nrcardio.2017.223. Epub 2018 Jan 18. Nat Rev Cardiol. 2018. PMID: 29345686 Review.

7

Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab.

Hu TY, Vaidya VR, Asirvatham SJ. Hu TY, et al. Vasc Health Risk Manag. 2016 Feb 17;12:35-44. doi: 10.2147/VHRM.S89130. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 26937198 Free PMC article. Review.

8

Antidotes for reversal of direct oral anticoagulants.

Dobesh PP, Bhatt SH, Trujillo TC, Glaubius K. Dobesh PP, et al. Pharmacol Ther. 2019 Dec;204:107405. doi: 10.1016/j.pharmthera.2019.107405. Epub 2019 Sep 12. Pharmacol Ther. 2019. PMID: 31521696 Review.

9

Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.

Huisman MV, Fanikos J. Huisman MV, et al. Am J Med. 2016 Nov;129(11S):S89-S96. doi: 10.1016/j.amjmed.2016.06.010. Epub 2016 Aug 26. Am J Med. 2016. PMID: 27569673 Free article. Review.

10

Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.

Milling TJ Jr, Kaatz S. Milling TJ Jr, et al. Am J Med. 2016 Nov;129(11S):S80-S88. doi: 10.1016/j.amjmed.2016.06.009. Epub 2016 Aug 27. Am J Med. 2016. PMID: 27575436 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

102 results

Results by year